A Study of MK-2225 in Healthy Participants (MK-2225-003)

Completed · Phase 1 · Has a placebo group

Conditions studied: Systemic Sclerosis

In brief

The purpose of the study is to learn about the safety of MK-2225, including how well people tolerate it. Researchers also want to learn what happens to different doses of MK-2225 in a person's body over time.

Key facts

Study ID

NCT06643390

Run by

Merck Sharp & Dohme LLC

People needed

32

Starts

2023-11-21

Expected to finish

2025-07-14

Last updated by the study team

2025-07-29

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• The key inclusion criteria include but are not limited to the following:
• Is in good health before randomization
• Body Mass Index (BMI) ≤32 kg/m\^2, inclusive

You may not qualify if…

• The key exclusion criteria include but are not limited to the following:
• History of clinically significant endocrine, gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases
• History of hypersensitivity to the MK-2225 drug substance, its inactive ingredients or the placebo (normal saline)

Where it is running

• Clinical Pharmacology of Miami (Site 0002) — Miami, Florida, United States
• Bio-Kinetic Clinical Applications, LLC dba QPS-MO (Site 0004) — Springfield, Missouri, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.